Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

China flag China · Delayed Price · Currency is CNY
4.200
+0.110 (2.69%)
Apr 29, 2026, 3:14 PM CST
38.61%
Market Cap 8.66B
Revenue (ttm) 1.06B
Net Income (ttm) -394.82M
Shares Out 2.06B
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 112,630,028
Average Volume 98,866,085
Open 4.000
Previous Close 4.090
Day's Range 4.000 - 4.300
52-Week Range 2.840 - 4.830
Beta 0.49
RSI 55.88
Earnings Date Apr 23, 2026

About SHE:300267

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutica... [Read more]

Sector Healthcare
Founded 2003
Employees 1,453
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300267
Full Company Profile

Financial Performance

In 2025, SHE:300267's revenue was 1.17 billion, an increase of 2.29% compared to the previous year's 1.14 billion. Losses were -379.82 million, 1.73% more than in 2024.

Financial Statements

News

There is no news available yet.